We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XOP icon
151
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.42B
$530K 0.01%
3,900
– –
GDX icon
152
VanEck Gold Miners ETF
GDX
$23B
$527K 0.01%
18,400
+5,000
+37% +$134K
BLU
153
DELISTED
BELLUS Health Inc.
BLU
$369K ﹤0.01%
+44,905
New +$419K
DSGN icon
154
Design Therapeutics
DSGN
$736M
$358K ﹤0.01%
34,881
– –
OPT
155
DELISTED
Opthea Limited American Depositary Shares
OPT
$235K ﹤0.01%
47,000
– –
MCHI icon
156
iShares MSCI China ETF
MCHI
$6.04B
$195K ﹤0.01%
4,100
– –
MKTX icon
157
MarketAxess Holdings
MKTX
$4.15B
$185K ﹤0.01%
662
– –
GDXJ icon
158
VanEck Junior Gold Miners ETF
GDXJ
$7.06B
$178K ﹤0.01%
5,000
– –
MELI icon
159
Mercado Libre
MELI
$91.3B
$144K ﹤0.01%
170
– –
DLB icon
160
Dolby
DLB
$4.72B
$113K ﹤0.01%
1,600
– –
ACHC icon
161
Acadia Healthcare
ACHC
$3.17B
$106K ﹤0.01%
1,287
+381
+42% +$31.4K
IPGP icon
162
IPG Photonics
IPGP
$3.89B
$99.4K ﹤0.01%
1,050
– –
UTHR icon
163
United Therapeutics
UTHR
$26.3B
$59K ﹤0.01%
212
-89
-30% -$22.5K
JMIA
164
Jumia Technologies
JMIA
$726M
$57.8K ﹤0.01%
18,000
– –
NKTR icon
165
Nektar Therapeutics
NKTR
$2.39B
$33.4K ﹤0.01%
987
– –
EQIX icon
166
Equinix
EQIX
$107B
$26.2K ﹤0.01%
40
– –
EVTC icon
167
Evertec
EVTC
$1.83B
$23.9K ﹤0.01%
739
– –
INFY icon
168
Infosys
INFY
$45B
$20.6K ﹤0.01%
1,130
– –
UMC icon
169
United Microelectronic
UMC
$48.9B
$17.9K ﹤0.01%
2,698
– –
TSM icon
170
TSMC
TSM
$2.09T
$1.25K ﹤0.01%
770
– –
ASR icon
171
Grupo Aeroportuario del Sureste
ASR
$8.03B
$157 ﹤0.01%
135
– –
CRBU icon
172
Caribou Biosciences
CRBU
$156M
– –
-66,300
Closed -$699K
EL icon
173
Estee Lauder
EL
$29B
– –
-1,348
Closed -$291K
LUNG icon
174
Pulmonx
LUNG
$49.4M
– –
-173,336
Closed -$2.89M
NPCE icon
175
Neuropace
NPCE
$505M
– –
-388,368
Closed -$1.46M
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.